- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04302571
Effects of Combined Aerobic and Resistance Training in Patients With Intermittent Claudication
Effects of Home-based Combined Aerobic and Resistance Training on Walking Capacity, Circulating Endothelial Progenitor Cells AND Endothelial Function in Patients With Intermittent Claudication
Exercise training improves walking capacity and regional perfusion in patients with Intermittent Claudication (IC). Endothelial Progenitor Cells (EPCs) and Endothelial Microparticles (EMPs) could play an important role in this process, promoting the healing of the diseased endothelium.
The investigators are going to measure EPCs and EMPs in a group of patients with IC and in a control group of healthy individuals before a treadmill test and 2, 24, and 48 hours after the test. Subsequently, a group of IC patients will be randomly assigned to perform a 12-week home-based exercise training program.
The investigators expect a significant increase of EMPs and EPCs after acute and chronic physical activity. We expect also a correlation between the increase of EMPs and EPCs and the improvement in walking capacity. Aim of the study is to demonstrate that acutely performed aerobic exercise could be able to promote the mobilization of EMPs and EPCs in patients with IC and that endothelial progenitor cells mobilization could play a pivotal role in exercise induced improvement of walking performance and endothelial function in subjects with IC.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
PG
-
Perugia, PG, Italien, 06132
- Ospedale "Santa Maria della Misericordia" di Perugia
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- history of stable intermittent claudication (PAD, stage II Fontaine)
- resting ankle-brachial index (ABI) <0,9 and the presence of occlusion or significant stenosis at the color-Doppler duplex ultrasound scanning
Exclusion Criteria:
- lower-limb ischemic rest pain or gangrene (Fontaine stages III and IV)
- inability to obtain the ABI value or to perform a walking test
- exercise tolerance limited by factors other than claudication (i.e., arrhythmias, cardiac symptoms or exaggerated blood pressure rise, severe obesity)
- end-stage liver or renal failure
- acute or chronic inflammatory conditions
- history of recent (<6 months) acute coronary syndrome, cerebrovascular event or inducible myocardial ischemia
- treatment with drugs known to affect walking capacity, including calcium-channel blockers, β-blockers and angiotensin-converting enzyme inhibitors.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Inget ingripande: Healthy control
Voluntary subjects without peripheral arterial disease
|
|
|
Sham Comparator: IC patients, no exercise
Patients with peripheral arterial disease stage II (intermittent claudication) on best medical treatment, given advices to perform regular aerobic activity
|
general recommendation to perform regular aerobic physical activity
|
|
Aktiv komparator: IC patients, exercise
Patients with peripheral arterial disease stage II (intermittent claudication) on best medical treatment, home-based combined physical exercise
|
Five training sessions weekly for 12 weeks are scheduled.
Each session lasts 60 minutes divided into 45 minutes of aerobic workout and 15 minutes of circuit training.
The aerobic workout consists of walking on a flat floor or on a slight uphill (maximum slope 3%): patients should walk until submaximal walking capacity (80% of their MWT) and rest as they would experience pain at the lower limbs; afterwards, they should start to walk again, once the pain was improved.
Resistance training consists of calisthenics exercises focused on trunk and lower limbs muscles (bicycle, flutter kicks, squats, lunges, calf raises, wall sits and power press) with at least 3 repetitions for each exercise, interspersed by 30 seconds recovery.
Duration of repetitions increases every 3 weeks.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Endothelial Microparticles (EMPs)
Tidsram: week 0 - week 12
|
hematological parameter, cells particles released by activated endothelium, measured by cytofluorimetry
|
week 0 - week 12
|
|
Endothelial Progenitor Cells (EPCs)
Tidsram: week 0 - week 12
|
hematological parameter, immature bone-marrow derived cells which repair the damaged endothelium, measured by cytofluorimetry
|
week 0 - week 12
|
|
Maximum Walking Time
Tidsram: week 0 - week 12
|
functional parameter, maximum walking capacity for an individual with IC measured through a treadmill walking test
|
week 0 - week 12
|
|
Pain-free Walking Time
Tidsram: week 0 - week 12
|
maximum walking capacity for an individual with IC without experiencing pain measured through a treadmill walking test
|
week 0 - week 12
|
|
Flow-mediated Dilation
Tidsram: week 0 - week 12
|
ultrasonographic evaluation of endothelial function
|
week 0 - week 12
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- APE-IC1
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .